陳琦媛 教授兼任所長

陳 琦 媛 (Chi-Yuan Chen)

職稱 (Job Title)：教授兼所長 (Professor and Director) 

主要學歷 (Education) ：Ph.D,陽明大學口腔醫學生物所博士 (Ph.D., Institute of Oral Biology, National Yang Ming University)

分機號碼 (Extension Number)：5113

電子郵件帳號 (Email Address)：d49417002@gmail.com

ORCID：https://orcid.org/0000-0003-4995-297X (開啟新視窗)

研究室 (Laboratory)：癌症轉譯醫學 (Cancer Translational Medicine)

研究室成員 (Laboratory Members)：研究生 (3 Graduate Students) / 專任助理 (3 Full-time Assistants)

研究專長 (Research Specialties)

Oncology、精準健康 (Precision Health)、Translational research

研究概要 (Research Summary)

本實驗室的研究主軸聚焦於癌症發生的分子機制探討，並篩選具潛力的活性藥物應用於治療。我們結合分子生物學、奈米技術與藥理學的研究方法，致力於解決腫瘤學領域的核心難題。主要研究方向包括：開發基於奈米顆粒的創新療法、剖析肺癌進展的分子路徑與抗藥性形成機制、研發天然物為基礎的抗癌療法，以及運用整合組學技術發掘癌症治療的新型標靶。透過上述跨領域的創新研究策略，提升精準醫療成效果，最終達成有效改善癌症治療的目標。

The main focus of the laboratory research is to investigate the mechanism of cancer drug resistance and to select active drugs for therapeutic use. The research strategy is to use the established platform of various cancer cell strains to explore carcinogenesis and screen drugs with anticancer activity, use animals and mice as the preclinical test model, and then analyze the mechanism of carcinogenesis or the gene or protein profiles that drugs may act on through the somatic platform, bioinformatics software, and pharmacogenetic profiling databases; in addition, the somatic platform is also used for the development of biomarkers in order to achieve the goal of improving the treatment of cancer effectively.

研究方向 (Research Directions)

  • 奈米技術與精準醫療 (Nanotechnology and Precision Medicine)
  • 藥物研發與癌症治療 (Drug Development and Cancer Therapy)
  • 多體學與標靶治療 (Multi-omics and Targeted Therapy)

最近研究主題 (Recent Research Topics)

  1. 肺癌標靶藥物抗藥性產生機轉。(Mechanisms of Targeted Drug Resistance in Lung Cancer)
  2. 運用天然物活性成分對抗肺癌標靶藥物抗藥性。(Utilizing Natural Active Compounds to Combat Targeted Drug Resistance in Lung Cancer)
  3. 研製細胞膜奈米劑型用於癌症靶向治療。(Development of Cell Membrane Nanofomulations for Targeted Cancer Therapy)

論文著作：五年內著作目錄 (Publications: Selected Papers from the Last Five Years)

  1. Chi-Yuan Chen, Kuo-Yen Huang, Chin-Chuan Chen, Ya-Hsuan Chang, Hsin-Jung Li, Tong-Hong Wang, Pan-Chyr Yang (2024 Nov). The role of PM2.5 exposure in lung cancer: mechanisms, genetic factors, and clinical implications. EMBO Mol Med.
  2. Jia-You Fang, Kuo-Yen Huang, Tong-Hong Wang, Zih-Chan Lin, Chin-Chuan Chen, Sui-Yuan Chang, En-Li Chen, Tai-Ling Chao, Shuenn-Chen Yang, Pan-Chyr Yang, Chi-Yuan Chen* (2024 Apr). Development of nanoparticles incorporated with quercetin and ACE2-membrane as a novel therapy for COVID-19. J Nanobiotechnology, 12;22(1):169.
  3. Chin-Chuan Chen#, Chi-Yuan Chen#, Chau-Ting Yeh, Yi-Tsen Liu, Yann-Lii Leu, Wen-Yu Chuang, Yin-Hwa Shih, Li-Fang Chou, Tzong-Ming Shieh, Tong-Hong Wang (#These authors have contributed equally to this work) (2023 Nov). Corylin Attenuates CCl4-Induced Liver Fibrosis in Mice by Regulating the GAS6/AXL Signaling Pathway in Hepatic Stellate Cells. International Journal of Molecular Science, 24(23):16936.
  4. Tong-Hong Wang, Kuo-Yen Huang, Chin-Chuan Chen, Ya-Hsuan Chang, Hsuan-Yu Chen, Chuen Hsueh, Yi-Tsen Liu, Shuenn-Chen Yang, Pan-Chyr Yang, Chi-Yuan Chen* (2023 Jun). PM2.5 promotes lung cancer progression through activation of the AhR-TMPRSS2-IL18 pathway. EMBO Molecular Medicine, 15(6):e17014.
  5. Tong-Hong Wang, Yann-Lii Leu, Chin-Chuan Chen, Hsin-Jung Li, Shuenn-Chen Yang, Kuo-Yen Huang, Chi-Yuan Chen* (2022 May). Psorachromene induces apoptosis and suppresses tumor growth in NSCLC cells harboring EGFR L858R/T790M/C797S. Phytotherapy Research, 36(5):2116.
  6. Chin-Chuan Chen#, Chi-Yuan Chen#, Shu-Fang Cheng, Tzong-Ming Shieh, Yann-Lii Leu, Wen-Yu Chuang, Kuang-Ting Liu, Shir-Hwa Ueng, Yin-Hwa Shih, Li-Fang Chou, Tong-Hong Wang* (#These authors contributed equally to the work) (2021, Sep). Hydroxygenkwanin Increases the Sensitivity of Liver Cancer Cells to Chemotherapy by Inhibiting DNA Damage Response in Mouse Xenograft Models. International Journal of Molecular Sciences , 22(18):9766.
  7. Kuo-Yen Huang, Tong-Hong Wang, Chin-Chuan Chen, Yann-Lii Leu, Hsin-Jung Li, Cai-Ling Jhong, Chi-Yuan Chen* (2021, Aug). Growth Suppression in Lung Cancer Cells Harboring EGFR-C797S Mutation by Quercetin. Biomolecules, 11(9):1271.
  8. Wei-Che Tseng#, Chi-Yuan Chen#, Ching-Yuh Chern#, Chu-An Wang, Wen- Chih Lee, Ying-Chih Chi, Shu-Fang Cheng, Yi-Tsen Kuo, Ya-Chen Chiu, Shih- Ting Tseng, Pei-Ya Lin, Shou-Jhen Liou, Yi-Chen Li, Chin-Chuan Chen*(# These authors contributed equally to this work) (2021, Apr). Targeting HR Repair as a Synthetic Lethal Approach to Increase DNA Damage Sensitivity by a RAD52 Inhibitor in BRCA2-Deficient Cancer Cells. International Journal of Molecular Sciences, 22(9):4422.
  9. Tong-Hong Wang, Chih-Ching Wu, Kuo-Yen Huang, Yann-Lii Leu, Shuenn-Chen Yang, Ci-Ling Chen, Chi-Yuan Chen* (2021, Jan). Integrated Omics Analysis of Non-Small-Cell Lung Cancer Cells Harboring the EGFR C797S Mutation Reveals the Potential of AXL as a Novel Therapeutic Target in TKI-Resistant Lung Cancer. Cancers , 13, 111.
  10. Tong-Hong Wang, Chin-Chuan Chen, Yann-Lii Leu, Yun-Shien Lee, Jang-Hau Lian, Hsi-Lung Hsieh, Chi-Yuan Chen* (2020, Dec). Palbociclib induces DNA damage and inhibits DNA repair to induce cellular senescence and apoptosis in oral squamous cell carcinoma. Journal of the Formosan Medical Association, S0929-6646(20)30609.
  11. Chi-Yuan Chen#, Jia-You Fang#, Chin-Chuan Chen#, Wen-Yu Chuang, Yann-Lii Leu, Shir-Hwa Ueng, Li-Shan Wei, Shu-Fang Cheng, Chuen Hsueh, Tong-Hong Wang* (#These authors have contributed equally to this work) (2020, Aug). 2-O- methylmagnolol, a magnolol derivative, suppresses hepatocellular carcinoma progression via inhibiting class I histone deacetylase expression. Frontiers in Oncology, 10:1319.
  12. Tong-Hong Wang, Chih-Ching Wu, Kuo-Yen Huang, Wen-Yu Chuang, Chuen Hsueh, Hsin-Jung Li, Chi-Yuan Chen* (2020, Apr). Profiling of subcellular EGFR interactome reveals hnRNP A3 modulates nuclear EGFR localization. Oncogenesis, 9:40.
  13. Chi-Yuan Chen#, Chin-Chuan Chen#, Wen-Yu Chuang, Yann-Lii Leu, Shir-Hwa Ueng, Chuen Hsueh, Chau-Ting Yeh, Tong-Hong Wang* (#These authors have contributed equally to this work.) (2020, Feb). Hydroxygenkwanin Inhibits Class I HDAC Expression and Synergistically Enhances the Antitumor Activity of Sorafenib in Liver Cancer Cells. Frontiers in Oncology, 10:216.
  14. Yann-Lii Leu, Tong-Hong Wang, Chih-Ching Wu, Kuo-Yen Huang, Yu-Wen Jiang, Yi-Chiung Hsu*, Chi-Yuan Chen* (2020, Feb). Hydroxygenkwanin suppresses non-small cell lung cancer progression by enhancing EGFR degradation. Molecules, 25(4), 941.
  15. Li-Fang Chou#, Chi-Yuan Chen#, Wan-Hua Yang, Chin-Chuan Chen, Junn- Liang Chang, Yann-Lii Leu, Miaw-Jene Liou, Tong-Hong Wang* (#These authors have contributed equally to this work.) (2019, Dec). Suppression of Hepatocellular Carcinoma Progression through FOXM1 and EMT Inhibition via Hydroxygenkwanin-Induced miR-320a Expression. Biomolecules, 10(1):20.
  16. Tong-Hong Wang, Chin-Chuan Chen, Kuo-Yen Huang, Ya-Min Shih, Chi-Yuan Chen*. (2019, Nov). High levels of EGFR prevent sulforaphane-induced reactive oxygen species-mediated apoptosis in non-small-cell lung cancer cells. Phytomedicine, 64:152926.
  17. Tong-Hong Wang, Yann-Lii Leu, Chin-Chuan Chen, Tzong-Ming Shieh, Jang-Hau Lian, Chi-Yuan Chen* (2019, Nov). Psorachromene Suppresses Oral Squamous Cell Carcinoma Progression by Inhibiting Long Non-coding RNA GAS5 Mediated Epithelial-Mesenchymal Transition. Frontiers in Oncology, 9: 1168.

實驗室活動剪影 (Laboratory Activities Snapshots)

  • 實驗室剪影 (Laboratory Snapshot)
  • 實驗室剪影2 (Laboratory Snapshot 2)
  • 實驗室剪影3 (Laboratory Snapshot 3)